Theravance Biopharma (TBPH) Revenue (QoQ) (2013 - 2026)

Theravance Biopharma (TBPH) Revenue (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Theravance Biopharma 864.82 Mn 470.15 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -61.43%
Dec 31, 2025 129.57%
Sep 30, 2025 -23.69%
Jun 30, 2025 70.23%
Mar 31, 2025 -17.95%
Dec 31, 2024 11.18%
Sep 30, 2024 18.32%
Jun 30, 2024 -1.70%
Mar 31, 2024 -17.43%
Dec 31, 2023 11.93%
Sep 30, 2023 14.14%
Jun 30, 2023 31.99%
Mar 31, 2023 -28.89%
Dec 31, 2022 17.65%
Sep 30, 2022 12.68%
Jun 30, 2022 -16.26%
Mar 31, 2022 -11.71%
Dec 31, 2021 13.28%
Sep 30, 2021 2.17%
Jun 30, 2021 -9.42%